Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 320 participants.
Also called NCT06435156
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 320 participants
- Registry
-
NCT06435156
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT06435156. Randomized; quadruple masking; primary purpose treatment. Start 2025-01-28 (actual); primary completion 2027-10-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes
- Acronym
- SOPHIST
- Condition
- Type 1 Diabetes
- Condition
- Heart Failure
- Intervention (Drug)
- Sotagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- University of Dundee
- Collaborator
- Lexicon Pharmaceuticals
- Collaborator
- Juvenile Diabetes Research Foundation
Record details
- Record id
cardio:ct-nct06435156- Content hash
62467e6b262877900217a4e3a8c0f932e5741ce6df1be59fc152af8a67806b34